Cxbladder Adoption Roll-Out Advances in New Zealand

Public Healthcare provider, Hawke’s Bay District Health Board, to roll out Cxbladder tests

Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) have signed an agreement with Hawke’s Bay District Health Board (HBDHB), further extending the adoption and commercial coverage of Cxbladder for the New Zealand population.

This latest announcement follows a succession of public healthcare providers, which have signed up within the last six months to offer Cxbladder testing as part of urology services within their regions, including Counties Manukau, Hauora Tairawhiti and Capital & Coast/Hutt Valley DHBs. The majority of New Zealand’s public health care providers now provide access to Cxbladder, with its ease of use, cost effectiveness and accuracy providing multiple benefits to patients and physicians.

Hawke’s Bay DHB, based in Hastings, covers an area along the North Island’s east coast, which includes Wairoa, Napier, Hastings and Waipukurau, serving a population, of which one-quarter are Māori and with a higher than average number of people aged 50 years or older.

Hawke’s Bay urologists, Kim Broome, David Mason, Leanne Shaw and urology registrar Josh Silverman are driving the adoption of Cxbladder in the region, where patients will be able to provide a urine specimen at their local diagnostic lab, potentially avoiding the need to travel to the urology clinic or hospital for investigation.

Mr Mason said he and the entire Hawke’s Bay urology team were delighted to have Cxbladder testing available for patients. “It will speed up the management of patient diagnosis and provide us with greater efficiencies in investigations for patients,” Mr Mason said.

Read more

Published by on 18/3/2019